Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Iron overload and cancer].

J F Blanc1, P Bioulac-Sage, C Balabaud

  • 1Service d'Hépato-Gastroentérologie, Hôpital Saint-André, France.

Bulletin De L'Academie Nationale De Medecine
|September 16, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatospecific MR contrast agent uptake on hepatobiliary phase can be used as a biomarker of marked β-catenin activation in hepatocellular adenoma.

European radiology·2020
Same author

Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE).

Oncoimmunology·2019
Same author

Multidisciplinary meetings specific to hepatocellular carcinoma: How to proceed?

Journal of visceral surgery·2019
Same author

Predictive factors of depressive symptoms of elderly patients with cancer receiving first-line chemotherapy.

Psycho-oncology·2016
Same author

FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort.

Annals of surgical oncology·2014
Same author

Interest of contrast-enhanced sonography to identify focal nodular hyperplasia with sinusoidal dilatation.

Diagnostic and interventional imaging·2013

Iron overload is a significant risk factor for cancer, especially liver cancer. Managing iron levels may help reduce cancer risk, particularly in individuals with genetic hemochromatosis.

Area of Science:

  • Oncology
  • Hepatology
  • Genetics

Context:

  • Iron overload is increasingly recognized as a risk factor for various cancers.
  • Hepatocellular carcinoma (HCC) risk is elevated in patients with genetic hemochromatosis, a condition causing iron accumulation.
  • The role of iron overload in HCC development, even without cirrhosis, is under investigation.

Purpose:

  • To explore the link between iron overload and cancer, with a focus on liver cancer.
  • To investigate the association between HFE gene mutations, iron overload, and hepatocellular carcinoma incidence.
  • To determine the significance of iron overload as a risk factor in hepatic carcinogenesis.

Summary:

  • Experimental and human data suggest iron overload promotes cancer, potentially via reactive oxygen species.

Related Experiment Videos

  • Hepatocellular carcinoma incidence is higher in cirrhosis from genetic hemochromatosis.
  • Mild iron overload is observed in over 50% of non-cirrhotic HCC cases, with HFE gene mutations present in 36% of these patients.
  • In black Africans, non-HFE-linked iron overload also elevates HCC risk.

    • Impact:

    • Highlights iron overload as a crucial, treatable factor in hepatic carcinogenesis.
    • Suggests potential therapeutic strategies targeting iron reduction to prevent liver cancer.
    • Emphasizes the need for further research into the mechanisms of iron-induced oncogenesis.